NAMI
National Alliance on Mental Illness
page printed from http://www.nami.org/
(800) 950-NAMI; info@nami.org
©2014
 

Facts on Access to Medications for People
with Depressive, Bipolar and Anxiety Illnesses

Conclusion

 
  • Access to anti-depressant, anti-anxiety and anti-convulsant medications versus barriers to treatment can mean the difference between hope and despair, recovery and struggle, life and death.
 
  • The stream of new medications that has reached millions of people with depressive, bipolar and anxiety disorders holds enormous potential.
  • Yet, barriers are being imposed by state policymakers that restrict access to needed medications for people with these disorders.
Based on the uniqueness of the medications and the individual patient characteristics of depressive, bipolar and anxiety disorders, it is critically important for state legislators to preserve and/or restore state funding for medications for people with depressive, bipolar and anxiety disorders.
  • Given many states’ budget crises, some may be tempted to limit access to medication and cut funding for services for those with mental illness. However, this is not the way to create an effective, efficient mental health system for those served by Medicaid and other public programs.
 
  • Access to medications for people with depressive, bipolar and anxiety disorders is essential for achieving the best possible clinical outcome as quickly as possible, which leads to the most cost-effective policy for legislators and physicians.
  • Based on the uniqueness of the medications and the individual patient characteristics of depressive, bipolar and anxiety disorders, it is critically important for state legislators to preserve and/or restore state funding for medications for people with depressive, bipolar and anxiety disorders.

Policymakers Toolkit Home

Back